Pore Therapy toner: Obagi’s exact formula and neighboring claims

The manufacturer names CLENZIderm M.D. Pore Therapy Exfoliating BHA Toner and describes a 2% salicylic-acid liquid exfoliant. Its own narrative concerns exfoliation, pores and clearer-looking skin. That identifies a toner, not a cleanser or a cream merely because other formats are pictured nearby. Exact toner page.

Keeping this name intact prevents the CLENZIderm family from becoming one undifferentiated preparation. The format comparison helps frame why product roles matter in a search that also includes creams. The narrative is an attributed manufacturer description. It does not establish permanent pore removal, diagnose a reader’s concern or measure the toner’s superiority over another finished product.

Obagi’s posted label was updated January 1, 2025. It identifies salicylic acid 2% as an acne treatment, with Uses involving acne pimples and prevention of new pimples. Those entries belong to this named Pore Therapy preparation, rather than serving as evidence for every pore-refining claim in the brand’s catalog. Dated acne record.

FDA’s explanation separates an active declaration, purpose, Uses and warnings. That is a useful distinction when a cosmetic-sounding product title sits beside acne-medication language. FDA field context. The label is not a head-to-head trial, and its date does not identify an individual bottle’s manufacture, purchase or clinical outcome. It supports a precise account of the submitted product record.

The label names SD alcohol 40-B, glycerin, chamomile extract, menthol, fragrance and other inactive components. Those details belong to Pore Therapy’s own complete declaration. They provide a more specific formula account than an acid percentage alone or a general statement that a toner feels refreshing. Inactive declaration.

The list does not supply every ingredient amount or establish which component would explain an individual symptom. It also does not permit reconstruction of a recipe. The percentage guide discusses why a matching salicylic figure leaves the preparation and outcomes unresolved. Here, the full declared mixture remains relevant, without a claim of independent chemical testing or an assumption about personal tolerance.

The website’s comparison area includes Obagi Nu-Derm Toner and Obagi-C C-Balancing Toner descriptions with alcohol-free and non-drying wording. Those statements concern the named neighboring products. They cannot describe Pore Therapy when its exact inactive list includes SD alcohol 40-B. Neighboring product descriptions and Pore Therapy ingredients.

The narrow finding is an attribution boundary, not a judgment that one toner is better or more irritating. A shared page or brand does not move a claim between formulas. The Versed document review is another place to examine separate products presented together. This review does not borrow a neighbor’s formula to fill a gap in Pore Therapy.

The label panel names Pore Therapy in a 5 fl oz, 148 mL bottle, and the structured entry identifies a liquid preparation. The NDC provides a way to locate the exact record. These are useful package specifications without proof that a particular seller supplied this version or quantity. Bottle and identity record.

FDA states that an NDC listing is not approval or verification of submitted product information. Identifier boundary. That prevents a traceable label from becoming a clinical endorsement. No subscription, order or fulfillment was tested for this document review. The unresolved transaction question concerns the actual item, separate from the product’s stated strength and promotional position.

The product page offers a Find a Physician link. That shows public navigation, not that this review contacted a clinician or that any reader received an assessment, referral or response. It supplies no basis to promise a particular service or infer personal suitability from the presence of the link. Professional navigation.

The acne label also retains warnings about irritation and dryness. Those are relevant despite the pore-refining and refreshing descriptions, without becoming instructions in this review. Warning record. The Minimalist review offers another discussion of formulation and evidence questions. No observed consultation or clinician signoff is claimed for either review’s document reading.

The useful remaining questions identify Pore Therapy, its actual ingredient version and the evidence behind the pore-refining outcome. The public descriptions and dated label do not settle personal comfort or provide a direct comparison with the other toner cards. Pore Therapy page and dated warnings.

FDA notes that manufacturers can change ingredients and labeling, making the exact version important. Label-version explanation. The version-record guide develops that point without deciding what someone should use. A clearer formula and package question is valuable on its own. It does not turn a physician link into clinical clearance, a bottle into a treatment duration or a brand-family description into a verified personal result.